Cancer Hospital, Chinese Academy of Medical Sciences
The CAMS Cancer Hospital is China's national cancer centre, leading regulatory-grade trials of domestic ADCs and PD-1 antibodies.
National Cancer Center of China; SKB264 (sac-TMT), disitamab vedotin, and many pivotal Chinese trials.
- National trials
- ADC development
Principal investigator of OptiTROP-Breast01, the Chinese trial that got the TROP2 ADC sacituzumab tirumotecan approved before any Western approval.
A breast oncologist who led Chinese pyrotinib and ADC trials and studies of ctDNA in HER2-positive disease.
Runs China's national cancer centre and the registry that reports the country's cancer statistics.
Led the RATIONALE trials of tislelizumab in lung cancer and many other Chinese registrational NSCLC studies.
Principal investigator of ESCORT, the trial that established camrelizumab in oesophageal squamous cell carcinoma.
A medical oncologist who has led many of China's registrational trials of domestically developed targeted agents and antibodies.
Pages like this
not linked directly; found by shared links- CompanyBeOne Medicines (formerly BeiGene)
Shares Jie Wang, National Medical Products Administration / Center for Drug Evaluation, Trials do not represent the people who get cancer, Regulatory divergence between regions.
- CompanySichuan Kelun-Biotech
Shares Binghe Xu, National Medical Products Administration / Center for Drug Evaluation, Sacituzumab tirumotecan.
- ProductCamrelizumab
Shares Jing Huang, CSCO guidelines (China), Regulatory divergence between regions, Oesophageal cancer.
- InstitutionSun Yat-sen University Cancer Center
Shares CSCO guidelines (China), National Medical Products Administration / Center for Drug Evaluation, Chinese Society of Clinical Oncology, Trials do not represent the people who get cancer.
- ProductTislelizumab
Shares Jie Wang, CSCO guidelines (China), Regulatory divergence between regions, Oesophageal cancer.
- ProductPyrotinib
- TrialESCORT-1st
Shares Jing Huang, Oesophageal cancer.
- ProductToripalimab
Shares CSCO guidelines (China), Regulatory divergence between regions, Oesophageal cancer.